Cyclacel Pharmaceuticals Inc (CYCC):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Cyclacel Pharmaceuticals Inc (CYCC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9960)・商品コード:DATA904C9960
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:60
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Cyclacel Pharmaceuticals Inc (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, CDK inhibitor and PLK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. The company’s seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.

Cyclacel Pharmaceuticals Inc (CYCC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Cyclacel Pharma Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 11
Licensing Agreements 12
Cyclacel Enters into Licensing Agreement with ManRos Therapeutics 12
Equity Offering 13
Cyclacel Pharma to Raise up to USD5 Million in Public Offering of Shares 13
Cyclacel Pharma Raises USD15.2 Million in Public Offering of Units 14
Cyclacel Pharma Raises USD1 Million in Public Offering of Shares 16
Cyclacel Pharma Raises USD2.8 Million in Private Placement of Shares 17
Cyclacel Pharma to Raise up to USD8.35 Million in Private Placement of Shares 18
Cyclacel Pharma Raises USD10 Million in Public Offering of Shares 19
Cyclacel Pharma Completes Public Offering Of Shares For US$10 Million 21
Cyclacel Pharma Completes Public Offering Of Shares For US$20 Million 23
Cyclacel Pharma Completes Private Placement Of Shares For US$3 Million 25
Asset Transactions 26
Celgene To Acquire Romidepsin Injection Patents From Cyclacel For US$5.5 Million 26
Cyclacel Pharmaceuticals Inc – Key Competitors 28
Cyclacel Pharmaceuticals Inc – Key Employees 29
Cyclacel Pharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 09, 2018: Cyclacel Pharmaceuticals reports second quarter 2018 financial results 31
May 14, 2018: Cyclacel Pharmaceuticals Announces First Quarter 2018 Financial Results 33
Mar 28, 2018: Cyclacel Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results 35
Nov 09, 2017: Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results 38
Aug 09, 2017: Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results 40
May 11, 2017: Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results 42
Mar 28, 2017: Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 44
Corporate Communications 46
Sep 12, 2018: Cyclacel Pharmaceuticals names Robert J. Spiegel as Board Director 46
May 22, 2018: CerSci Therapeutics Names Dr. David U’Prichard To Advisory Board 47
Product News 48
09/11/2018: Cyclacel starts Phase lb/ll trial BRCA mutant breast cancer 48
Clinical Trials 49
Feb 21, 2018: Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations 49
Dec 12, 2017: Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting 50
Nov 01, 2017: Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting 52
Apr 02, 2017: Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways 53
Mar 07, 2017: Cyclacels CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI 55
Feb 23, 2017: Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia 56
Other Significant Developments 58
Jan 09, 2018: Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018 58
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cyclacel Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cyclacel Pharma Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 11
Cyclacel Enters into Licensing Agreement with ManRos Therapeutics 12
Cyclacel Pharma to Raise up to USD5 Million in Public Offering of Shares 13
Cyclacel Pharma Raises USD15.2 Million in Public Offering of Units 14
Cyclacel Pharma Raises USD1 Million in Public Offering of Shares 16
Cyclacel Pharma Raises USD2.8 Million in Private Placement of Shares 17
Cyclacel Pharma to Raise up to USD8.35 Million in Private Placement of Shares 18
Cyclacel Pharma Raises USD10 Million in Public Offering of Shares 19
Cyclacel Pharma Completes Public Offering Of Shares For US$10 Million 21
Cyclacel Pharma Completes Public Offering Of Shares For US$20 Million 23
Cyclacel Pharma Completes Private Placement Of Shares For US$3 Million 25
Celgene To Acquire Romidepsin Injection Patents From Cyclacel For US$5.5 Million 26
Cyclacel Pharmaceuticals Inc, Key Competitors 28
Cyclacel Pharmaceuticals Inc, Key Employees 29
Cyclacel Pharmaceuticals Inc, Other Locations 30
Cyclacel Pharmaceuticals Inc, Subsidiaries 30

List of Figures
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Cyclacel Pharmaceuticals Inc (CYCC):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9960)販売に関する免責事項を必ずご確認ください。
★調査レポート[Cyclacel Pharmaceuticals Inc (CYCC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆